GuideHaematology
A-HIPI: Advanced-stage Hodgkin Lymphoma International Prognostic Index
Reading sheet on the HoLISTIC model estimating 5-year PFS and OS in advanced-stage classic Hodgkin lymphoma in adults aged 18–65.
Updated 3 November 2026
When to use it
Adults aged 18–65 with newly diagnosed advanced-stage classic Hodgkin lymphoma (IIB, III or IV) receiving standard chemotherapy; it replaces the IPS as an individual risk estimate.
What it is and for whom
Cox model developed by the HoLISTIC consortium from 4,022 patients in 8 phase III trials (1996–2014) and externally validated in 1,431 patients from 4 registries. It estimates individual 5-year PFS and OS probabilities in advanced classic Hodgkin lymphoma treated with standard chemotherapy (ABVD, BEACOPP and variants).
Keep reading in the app
- Variables
- Interpretation
- Limitations
Practical tip
It uses continuous variables (age and lymphocytes with non-linear effects) instead of the IPS dichotomous cut-offs: better calibration and better discrimination for OS.
2 more practical tips in the app.
Reference
- Rodday AM, Parsons SK, Upshaw JN, et al. The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: development and validation of a clinical prediction model from the HoLISTIC Consortium. J Clin Oncol. 2023;41(11):2076-2086.
- Maurer MJ, Parsons SK, Upshaw JN, et al. The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online tool. Blood Adv. 2025;9(6):1366-1369.
Official source: A-HIPI risk-group tool (HoLISTIC / Mayo Clinic)
A support tool for healthcare professionals: it guides and does not replace clinical judgement.
